New hope for mastocytosis patients: expanded access to bezuclastinib

NCT ID NCT06915766

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This program offers bezuclastinib, an investigational drug, to adults with systemic mastocytosis who have tried and failed at least one approved therapy or have no other good options. The goal is to provide disease control when standard treatments are not working. Participants must be 18 or older and able to swallow tablets.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC MASTOCYTOSES, INDOLENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • AIR Care

    AVAILABLE

    Dallas, Texas, 75231, United States

    Contact Email: •••••@•••••

  • AllerVie Health

    AVAILABLE

    Glenn Dale, Maryland, 20769, United States

    Contact Email: •••••@•••••

  • Allergy Associates of Utah

    AVAILABLE

    Sandy City, Utah, 84093, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Boston Specialists

    AVAILABLE

    Boston, Massachusetts, 02111, United States

    Contact Email: •••••@•••••

  • Dana Farber Cancer Institute

    AVAILABLE

    Boston, Massachusetts, 02215, United States

    Contact Email: •••••@•••••

  • Dartmouth-Hitchcock Medical Center

    AVAILABLE

    Lebanon, New Hampshire, 03756, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Duke Blood Cancer Center

    AVAILABLE

    Durham, North Carolina, 27705, United States

    Contact Email: •••••@•••••

  • Indiana University Health

    AVAILABLE

    Indianapolis, Indiana, 46202, United States

    Contact Email: •••••@•••••

  • Mayo Clinic

    AVAILABLE

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering Cancer Center

    AVAILABLE

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Michigan Medicine- University of Michigan

    AVAILABLE

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

  • Northwest Medical Specialties

    AVAILABLE

    Tacoma, Washington, 98405, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Orso Health/Modena Asthma Allergy

    AVAILABLE

    La Jolla, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Scripps Green Hospital

    AVAILABLE

    La Jolla, California, 92037, United States

    Contact Email: •••••@•••••

  • Sneeze Wheeze & Itch Associates LLC Clinical Research Center

    AVAILABLE

    Normal, Illinois, 61761, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

  • Texas Children's Hospital

    AVAILABLE

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ohio State University Wexner Medical Center

    AVAILABLE

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

  • The University of Texas, MD Anderson Cancer Center

    AVAILABLE

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • UCLA Ronald Reagan Medical Center

    AVAILABLE

    Los Angeles, California, 90095, United States

    Contact Phone: •••-•••-••••

    Contact Email: •••••@•••••

  • Walter Reed

    AVAILABLE

    Bethesda, Maryland, 20889, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.